1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Wearable Injectors Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Wearable Injectors Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Wearable Injectors Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. On-body Wearable Injectors
6.3.2. Off-body Wearable Injectors
6.4. Market Attractiveness Analysis, by Type
7. Global Wearable Injectors Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Oncology
7.3.2. Diabetes
7.3.3. Autoimmune Disorders
7.3.4. Cardiovascular Diseases
7.3.5. Infectious Diseases
7.3.6. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Wearable Injectors Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Home Care Settings
8.3.4. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Wearable Injectors Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Wearable Injectors Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2017–2031
10.3.1. On-body Wearable Injectors
10.3.2. Off-body Wearable Injectors
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Oncology
10.4.2. Diabetes
10.4.3. Autoimmune Disorders
10.4.4. Cardiovascular Diseases
10.4.5. Infectious Diseases
10.4.6. Others
10.5. Market Value Forecast, by End-user, 2017–2031
10.5.1. Hospitals
10.5.2. Clinics
10.5.3. Home Care Settings
10.5.4. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Type
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Wearable Injectors Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. On-body Wearable Injectors
11.3.2. Off-body Wearable Injectors
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Oncology
11.4.2. Diabetes
11.4.3. Autoimmune Disorders
11.4.4. Cardiovascular Diseases
11.4.5. Infectious Diseases
11.4.6. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Home Care Settings
11.5.4. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Wearable Injectors Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2017–2031
12.3.1. On-body Wearable Injectors
12.3.2. Off-body Wearable Injectors
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Oncology
12.4.2. Diabetes
12.4.3. Autoimmune Disorders
12.4.4. Cardiovascular Diseases
12.4.5. Infectious Diseases
12.4.6. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Home Care Settings
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Wearable Injectors Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2017–2031
13.3.1. On-body Wearable Injectors
13.3.2. Off-body Wearable Injectors
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Oncology
13.4.2. Diabetes
13.4.3. Autoimmune Disorders
13.4.4. Cardiovascular Diseases
13.4.5. Infectious Diseases
13.4.6. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Home Care Settings
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Wearable Injectors Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type, 2017–2031
14.3.1. On-body Wearable Injectors
14.3.2. Off-body Wearable Injectors
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Oncology
14.4.2. Diabetes
14.4.3. Autoimmune Disorders
14.4.4. Cardiovascular Diseases
14.4.5. Infectious Diseases
14.4.6. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Home Care Settings
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. BD
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. F. Hoffmann-La Roche Ltd.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Tandem Diabetes Care, Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Insulet Corporation
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Ypsomed AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. West Pharmaceutical Services, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. CeQur Corporation
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Debiotech S.A.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Sensile Medical AG (Gerresheimer AG)
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. United Therapeutics Corporation
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/